Already a DIA Member? Sign in. Not a member? Join.

Sign in

Forgot User ID? or Forgot Password?

Not a Member?

Create Account and Join

Hilton Lac-Leamy

Nov 14, 2024 7:30 AM - Nov 15, 2024 4:10 PM

3 Boulevard du Casino, Gatineau, QC J8Y 6X4, Canada

Canada Annual Meeting

The Canada Annual Meeting offers three tracks, Regulatory, Clinical, Safety and Pharmacovigilance!

Session 3, Tracks B & C: Pre- and Post-marketing Surveillance: Best Practices

Session Chair(s)

Nadiya  Jirova, MSc

Nadiya Jirova, MSc

Manager, Bureau of Biologics, Radiopharmaceuticals and Self-Care Products

Health Canada, Canada

Myriam  Salem, MSc

Myriam Salem, MSc

Good Pharmacovigilance Practices National Coordinator

Health Canada, Canada

In this session health Canada will provide practical guidance for several areas of pre- and post-market surveillance. This session will provide practical advice on reporting Adverse Drug Reactions (ADRs) from various sources. The session will kick off with the Canada Vigilance is Health Canda’s post-market surveillance program that collects and assesses reports of suspected adverse reactions to health products marketed in Canada. A second presentation will give an overview of Health Canada's Vigilance framework for cannabis and cannabis products and reporting ADRs to the Canada Vigilance Program. This session will conclude with two presentations from the pre-market and post-market inspectorate program, the Good Clinical Practices Inspection program and the Good Pharmacovigilance Practices (GVP) Inspection program to address common industry questions to address common industry questions including tips on how to prepare for GVP inspections.

Learning Objective :
  • Identify cases that must be reported to Health Canada under Food and Drug Regulations
  • Identify cases that must be reported under the Cannabis Regulations
  • Describe Inspectorate’s expectations during Health Canada GCP inspections
  • Describe Inspectorate’s expectations during Health Canada GVP inspections

Speaker(s)

Silas  Da Graça, MSc

Best Practices on Reporting Adverse Reactions from Various Sources

Silas Da Graça, MSc

Health Canada, Canada

A/Manager, Adverse Reaction Monitoring and Information Section

Safia  Hassan

Health Canada's Vigilance Framework for Cannabis and Cannabis Products

Safia Hassan

Health Canada, Canada

Scientific Evaluator

Hocine  Abid, MD, MBA

Speaker

Hocine Abid, MD, MBA

Health Canada, Canada

National Manager, Regulatory Operations and Enforcement Branch

Fadi  Sader, PhD

GVP Inspection Trends, Ongoing Initiatives, and Best Practices

Fadi Sader, PhD

Health Canada, Canada

Regional Regulatory Compliance and Enforcement Officer

Have an account?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.